Results 51 to 60 of about 63,206 (209)

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study

The Saudi Journal of Gastroenterology, 2017
Background/Aims: The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs.
Hamad Al Ashgar, Musthafa C Peedikayil, Mohammed Al Quaiz, Fahad Al Sohaibani, Abdulrahman Al Fadda, Mohammed Q Khan, Einar Thoralsson, Sahar Al Thawadi, Ahmed Al Jedai, Khalid Al Kahtani   +9 more
doaj   +1 more source

Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. [PDF]

, 2017
BackgroundThere is ongoing controversy regarding abacavir use in the treatment of HIV infection and the risk of subsequent development of cardiovascular disease.
Baxi, Sanjiv M, Dorjee, Kunchok, Hubbard, Alan, Reingold, Arthur L   +3 more
core   +3 more sources

Upper Airway Obstruction due to Kaposi Sarcoma—Presenting Sign of HIV: Case Report and Review

The Laryngoscope, EarlyView.
This study presents a case of undiagnosed HIV presenting with Kaposi sarcoma (KS) of the head and neck with acute upper airway obstruction (UAO) and provides an updated scoping literature review to examine the patient characteristics, lesion characteristics, interventions, and outcomes of KS cases with UAO from the pharynx, larynx, and/or trachea.
Zachary A. Wykoff, Logan F. McColl, Robert A. Baiocchi, Matthew O. Old   +3 more
wiley   +1 more source

Treatment failure and drug resistance in HIV‐positive patients on tenofovir‐based first‐line antiretroviral therapy in western Kenya

Journal of the International AIDS Society, 2016
Introduction Tenofovir‐based first‐line antiretroviral therapy (ART) is recommended globally. To evaluate the impact of its incorporation into the World Health Organization (WHO) guidelines, we examined treatment failure and drug resistance among a ...
Katherine Brooks, Lameck Diero, Allison DeLong, Maya Balamane, Marissa Reitsma, Emmanuel Kemboi, Millicent Orido, Wilfred Emonyi, Mia Coetzer, Joseph Hogan, Rami Kantor   +10 more
doaj   +1 more source

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). [PDF]

, 2016
We conducted a longitudinal and cross-sectional analysis of depressive symptomology in iPrEx, a randomized, placebo-controlled trial of daily, oral FTC/TDF HIV pre-exposure prophylaxis (PrEP) in men and transgender women who have sex with men. Depression-
Amico, K Rivet, Avelino-Silva, Vivian I, Burns, David, Chodacki, Piotr, Defechereux, Patricia A, Fernandez, Telmo, Glidden, David V, Grant, Robert M, iPrEx Study Team, Liu, Albert Y, Mayer, Kenneth H, McMahan, Vanessa M, Mehrotra, Megha, Vargas, Lorena   +13 more
core   +1 more source

A Case Report of a Special Type of Multiple Myeloma: Kappa Light Chain‐Only

Organ Medicine, EarlyView.
This case illustrates the clinical course of a patient diagnosed with kappa light chain‐only multiple myeloma, a rare subtype of multiple myeloma. Of note, light chain multiple myeloma is characterized by rapid disease progression and severe target organ damage.
Yanhua Dai, Yuanyue Guan, Shiwei Cui, Yuan Gao, Zhipeng Zhao, Rui Li, Li Song, Xiuying Zhao, Runqing Li   +8 more
wiley   +1 more source

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. [PDF]

, 2015
Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding ...
D:A:D study group, ., ESPRIT study group, ., Fux, CA, INSIGHT study group, ., Johnson, MA, Kirk, O, Law, M, Lundgren, JD, Mocroft, A, Moranne, O, Morlat, P, Neuhaus, J, Reiss, P, Ross, M, Royal Free Hospital Clinic Cohort, ., Ryom, L, SMART study group, ., Smith, C, Wentworth, D   +18 more
core  

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, EarlyView.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source

Mitotherapy inhibits against tenofovir induced nephrotoxicity on rat renal proximal tubular cells

Biochemistry and Biophysics Reports
Tenofovir, as nucleotide reverse transcriptase inhibitors (NRTIs), is used to prevent and cure HIV/AIDS. Ample evidence confirmed that the nephrotoxicity of tenofovir has been linked to mitochondrial dysfunction.
Mir-Jamal Hosseini, Aysan Hassanbeigloo, Hamideh Abbasi, Abdollah Arjmand, Fatemeh Sherkat, Jalal Pourahmad   +5 more
doaj   +1 more source

Mucosal effects of tenofovir 1% gel

eLife, 2015
Tenofovir gel is being evaluated for vaginal and rectal pre-exposure prophylaxis against HIV transmission. Because this is a new prevention strategy, we broadly assessed its effects on the mucosa.
Florian Hladik, Adam Burgener, Lamar Ballweber, Raphael Gottardo, Lucia Vojtech, Slim Fourati, James Y Dai, Mark J Cameron, Johanna Strobl, Sean M Hughes, Craig Hoesley, Philip Andrew, Sherri Johnson, Jeanna Piper, David R Friend, T Blake Ball, Ross D Cranston, Kenneth H Mayer, M Juliana McElrath, Ian McGowan   +19 more
doaj   +1 more source